Integral Health Asset Management LLC Buys 350,000 Shares of Biohaven Ltd. $BHVN

Integral Health Asset Management LLC lifted its position in Biohaven Ltd. (NYSE:BHVN) by 116.7% during the third quarter, HoldingsChannel.com reports. The fund owned 650,000 shares of the company’s stock after purchasing an additional 350,000 shares during the period. Integral Health Asset Management LLC’s holdings in Biohaven were worth $9,756,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Norges Bank acquired a new position in Biohaven during the second quarter valued at approximately $12,735,000. Bellevue Group AG raised its holdings in Biohaven by 37.3% in the second quarter. Bellevue Group AG now owns 2,802,853 shares of the company’s stock worth $39,548,000 after purchasing an additional 762,000 shares during the period. Cubist Systematic Strategies LLC bought a new position in shares of Biohaven during the second quarter worth $9,289,000. BNP Paribas Financial Markets boosted its position in shares of Biohaven by 6,907.3% during the second quarter. BNP Paribas Financial Markets now owns 628,622 shares of the company’s stock worth $8,870,000 after purchasing an additional 619,651 shares in the last quarter. Finally, JPMorgan Chase & Co. grew its holdings in shares of Biohaven by 31.2% in the 2nd quarter. JPMorgan Chase & Co. now owns 2,572,042 shares of the company’s stock valued at $36,292,000 after buying an additional 612,209 shares during the period. Institutional investors own 88.78% of the company’s stock.

Biohaven Stock Down 3.4%

Shares of Biohaven stock opened at $9.57 on Friday. Biohaven Ltd. has a 52-week low of $7.48 and a 52-week high of $31.18. The company has a debt-to-equity ratio of 4.59, a quick ratio of 3.18 and a current ratio of 3.18. The business’s 50 day simple moving average is $11.50 and its 200 day simple moving average is $12.45. The firm has a market cap of $1.01 billion, a PE ratio of -1.37 and a beta of 1.15.

Biohaven (NYSE:BHVN) last posted its quarterly earnings data on Monday, March 2nd. The company reported ($1.21) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.22) by $0.01. On average, analysts predict that Biohaven Ltd. will post -8.9 earnings per share for the current fiscal year.

Analyst Ratings Changes

BHVN has been the subject of a number of recent analyst reports. Citigroup restated a “buy” rating on shares of Biohaven in a research report on Friday, December 26th. JPMorgan Chase & Co. decreased their target price on Biohaven from $47.00 to $15.00 and set an “overweight” rating for the company in a research note on Thursday, November 20th. Royal Bank Of Canada increased their price target on Biohaven from $22.00 to $23.00 and gave the stock an “outperform” rating in a report on Tuesday, March 3rd. Leerink Partners reaffirmed an “outperform” rating and set a $15.00 price target on shares of Biohaven in a research report on Tuesday, March 3rd. Finally, Morgan Stanley cut their price objective on Biohaven from $26.00 to $21.00 and set an “overweight” rating on the stock in a report on Tuesday, January 6th. Three investment analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $24.93.

Biohaven Company Profile

Biohaven Ltd. (NYSE BHVN) is a clinical-stage biopharmaceutical company dedicated to developing and commercializing therapies for neurological and neurovascular diseases. Founded in 2013 as a spin-out from Yale University, Biohaven focuses on addressing high-unmet medical needs through innovative small-molecule and peptide-based platforms. The company is headquartered in New Haven, Connecticut, and maintains research activities across the United States, with collaborative ties in Europe and Asia via strategic partnerships.

The company’s most advanced program centers on calcitonin gene-related peptide (CGRP) receptor antagonists for the acute and preventive treatment of migraine.